Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

TBPH stock hub

Theravance Biopharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TBPHis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

876.9M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

TBPH

In the news

Latest news · TBPH

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E7.7

P25 12.3P50 18.4P75 33.1

Trailing P/E7.7

P25 14.9P50 23.2P75 38.5

ROE50.2

P25 -105.6P50 -46.5P75 -3.1

ROIC-3.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TBPH market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

233

Groups with data

Currency

USD

Showing 233 of 233 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001583107
Company name	Theravance Biopharma, Inc.
Country	United States
Country code	US
Cusip	G8807B106
Employees	90
Employees Change	-7%
Employees Change Percent	-7.22
Enterprise value	$522.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	KYG8807B1068
Last refreshed	2026-05-10
Market cap	$876.9M
Market cap category	Small-Cap
Price	$17.01
Price currency	USD
Rev Per Employee	1,219,722.22x
Sector	Healthcare
Sic	2834
Symbol	TBPH
Website	https://www.theravance.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	13.06%
EV Earnings	4.56x
EV Sales Forward	4.51x
EV/EBIT	104.93x
EV/EBITDA	79.49x
EV/FCF	1.95x
EV/Sales	4.76x
FCF yield	30.65%
Forward P/E	7.72x
P/B ratio	3.02x
P/E ratio	7.69x
P/S ratio	7.99x
PS Forward	7.57x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	4.54%
EBITDA Margin	5.99%
FCF margin	244.81%
Gross margin	71.04%
Gross Profit	$78M
Gross Profit Growth	210.21%
Gross Profit Growth Q	201.58%
Net Income	$114.5M
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Net Income Growth3 Y	-49.24%
Pretax Margin	124.72%
Profit Margin	104.34%
Profit Per Employee	$1.3M
Profitable Years	1
ROA	0.76
Roa5y	-11.96
ROCE	1.13
ROE	50.17
ROIC	-3.66
Roic5y	-62.9

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-0.54%
Cagr1y	70.33%
Cagr3y	14.5%
Cagr5y	-2.94%
EPS Growth Quarters	4
EPS Growth Years	1
EPS Growth3 Y	-43.75
FCF Growth	732.4%
FCF Growth Q	70.26%
OCF Growth	726.36%
OCF Growth Q	70.26%
Revenue Growth	68.2x
Revenue Growth Q	15.02x
Revenue Growth Quarters	12x
Revenue Growth Years	3x
Revenue Growth3 Y	31.24x
Revenue Growth5 Y	10.63x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.27
Assets	$472.3M
Cash	$394.7M
Current Assets	$417.6M
Current Liabilities	$31.8M
Debt	$40.5M
Debt EBITDA	$6.16
Debt Equity	$0.14
Debt FCF	$0.15
Equity	$290.6M
Interest Coverage	2.74
Liabilities	$181.7M
Long Term Assets	$54.7M
Long Term Liabilities	$149.9M
Net Cash	$354.2M
Net Cash By Market Cap	$40.39
Net Cash Growth	328.25%
Net Debt EBITDA	$-53.86
Net Debt Equity	$-1.22
Net Debt FCF	$-1.32
Tangible Book Value	$290.6M
Tangible Book Value Per Share	$5.64
WACC	5.23

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	13.14
Net Working Capital	$1.9M
Quick ratio	12.91
Working Capital	$385.9M
Working Capital Turnover	$0.44

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5.48%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-5.24%
1Y total return	70.27%
200-day SMA	16.09
3Y total return	50.13%
50-day SMA	15.74
50-day SMA vs 200-day SMA	50under200
5Y total return	-13.87%
All Time High	43.44
All Time High Change	-60.84%
All Time High Date	2017-06-26
All Time Low	6.1
All Time Low Change	178.85%
All Time Low Date	2021-09-15
ATR	0.46
Beta	0.19
Beta1y	1.23
Beta2y	1.11
Ch YTD	-9.09
High	17.07
High52	21.03
High52 Date	2026-01-22
High52ch	-19.12%
Low	16.61
Low52	8.33
Low52 Date	2025-05-14
Low52ch	104.2%
Ma50ch	8.06%
Price vs 200-day SMA	5.75%
RSI	59.47
RSI Monthly	62.66
RSI Weekly	52.14
Sharpe ratio	1.19x
Sortino ratio	1.94
Total Return	-5.48%
Tr YTD	-9.09
Tr1m	2.72%
Tr1w	1.31%
Tr3m	-16.94%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	5
Analyst Price Target Top	$19.25
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.06
Earnings Revenue Estimate	17,548,000x
Earnings Revenue Estimate Growth	14.04x
Operating Income	$5M
Operating margin	4.54
Price target	$18.4
Price Target Change	$8.17
Price Target Change Top	$13.17

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	24,585,505%
Float Percent	47.69%
Shares Insiders	5.7%
Shares Institutions	49.61%
Shares Out	51,553,005
Shares Qo Q	-3.34%
Shares Yo Y	5.48%
Short Float	21.17%
Short Ratio	9.29
Short Shares	10.1

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$250.6M
Average Volume	345,372.35x
Bv Per Share	5.64
CAPEX	$-42,000
Ch10y	-5.24
Ch1m	2.72
Ch1w	1.31
Ch1y	70.27
Ch3m	-16.94
Ch3y	50.13
Ch5y	-13.87
Ch6m	15.32
Change	-0.06%
Change From Open	1.37
Close	17.02
Days Gap	-1.41
Depreciation Amortization	1,594,000
Dollar Volume	4,041,473.9
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$5M
EBITDA	$6.6M
EPS	$2.21
F Score	7
FCF	$268.7M
FCF EV Yield	51.41x
FCF Per Share	$5.21
Financing CF	-7,971,000
Fiscal Year End	December
Founded	2,013
Graham Number	16.75175
Graham Upside	-1.52
Income Tax	$22.4M
Investing CF	-83,323,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-23
Lynch Fair Value	$11.05
Lynch Upside	-35.01
Ma150	17.07
Ma150ch	-0.37%
Ma20	16.74
Ma20ch	1.61%
Net CF	177,487,000
Next Earnings Date	2026-08-11
Open	16.78
Optionable	Yes
P FCF Ratio	3.26
P OCF Ratio	3.26
Position In Range	86.96
Ppne	28,540,000
Price Date	2026-05-08
Price EBITDA	$133
Ptbv Ratio	3.02
Relative Volume	0.69x
Revenue	109,775,000x
SBC By Revenue	16.49x
Share Based Comp	18,103,000
Tax By Revenue	20.38x
Tax Rate	16.34%
Tr6m	15.32%
Us State	California
Volume	237,594
Z Score	1.04

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does TBPH pay a dividend?

Capital-return profile for this ticker.

Performance

TBPH stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TBPH?

Insider, institutional, and short-interest positioning.

Institutional ownership

+49.6%

Float: +47.7% of shares outstanding

Insider ownership

+5.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

TBPH momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

59.5

Neutral momentum band

Price vs 200-day MA

+5.8%

50/200-day relationship not available

Beta (5Y)

0.19

Less volatile than the market

Sharpe ratio

1.19

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TBPH

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TBPH stock rating?

Theravance Biopharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TBPH analysis?

The full report lives at /stocks/TBPH/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TBPH?

The latest report frames TBPH around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TBPH page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.